Quick Answer
Sionna Therapeutics, Inc. reported Stockholders Equity of $306.83 million for the year ending 2025.
- Sionna Therapeutics, Inc. showed an increase of +287.4% in Stockholders Equity from 2024 to 2025.
- This data is from Sionna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 2, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2024: -$126.08 million | Q2 2024: -$133.77 million | Q3 2024: -$148.55 million | Q1 2025: $351.77 million | Q2 2025: $336.43 million | Q3 2025: $321.67 million.
- Over the full 3 years of available data (2023 to 2025), Sionna Therapeutics, Inc.'s Stockholders Equity has grown by 367.1%.
- Historical annual values: Fiscal year 2025: $306.83 million | Fiscal year 2024: -$163.71 million | Fiscal year 2023: -$114.88 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: